The mission of the Boehringer Ingelheim Clinical Research Grants Program for investigators and collaborative partners is to support the advancement of scientific knowledge regarding Boehringer Ingelheim´s products and their related therapeutic areas of interest.
The Clinical Research Grants Program is designed to enable research that has the potential to improve the treatment of disease, patient outcomes and the quality of health care. Support is awarded based on the scientific merit of each proposal received.
The program is offered to all academic and community based scientists, individually or through consortia. It allows investigators and collaborative partners to submit their proposals for consideration where they work independently - Investigator Initiated Studies (IIS) - or work collaboratively with Boehringer Ingelheim in External Collaborative Research (ECR) to execute their research.
>
Boehringer lngelheim does not assume regulatory responsibility for either type of clinical research
>
Investigators serve as Sponsor-Investigator for both IIS and ECR studies
>
May involve financial support and/or provision of Boehringer Ingeheim drugs or compounds
>
Funding level needs to represent e.g. actual costs of service and materials
>
Can include interventional or non-interventional study designs
Investigator Initiated Studies (IIS)
>
Grant funding to support interventional and non-interventional studies
>
Sponsor-Investigators independently propose and conduct their study
External Collaborative Research (ECR)
>
Grant funding to support interventional and non-interventional studies where Boehringer lngelheim contributes complementary to the expertise of the collaborative partner, who is the regulatory sponsor of the study. Contribution by Boehringer Ingelheim can be providing intellectual input to the study design, protocol, statistical analysis plan, clinical study report and publication.
>
The collaborative partner must assume all responsibility (including under applicable regulations) and retain ultimate control over the conduct of the ECR including acting as a regulatory sponsor.